Loading...
Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
Brentuximab vedotin (SGN-35) is an antibody–drug conjugate with a high selectivity against CD30(+) cell lines and more than 300-fold less activity against antigen-negative cells. In the last years, the results of many in vitro and in vivo studies have led to the fast approval of this drug to treat l...
Na minha lista:
| Udgivet i: | Int J Mol Sci |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4964432/ https://ncbi.nlm.nih.gov/pubmed/27376285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms17071056 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|